Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference
01 mars 2023 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701
16 févr. 2023 07h30 HE
|
Inozyme Pharma Inc.
- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial - - Rapid and...
Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023
06 févr. 2023 07h30 HE
|
Inozyme Pharma Inc.
- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE) – BOSTON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq:...
Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress
09 janv. 2023 08h30 HE
|
Inozyme Pharma Inc.
- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at virtual event on Thursday, Feb. 16, 2023 – - Significant clinical and scientific...
Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency
05 déc. 2022 08h30 HE
|
Inozyme Pharma Inc.
- Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more than tripling prior estimate - - Company estimates addressable patient...
Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
01 déc. 2022 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates
10 nov. 2022 08h30 HE
|
Inozyme Pharma Inc.
- Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of 2022 – - Topline data from Phase 1/2 clinical trial of INZ-701 in ABCC6...
Inozyme Pharma to Participate in Upcoming Investor Conferences
07 nov. 2022 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial
03 nov. 2022 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database
31 oct. 2022 07h30 HE
|
Inozyme Pharma Inc.
- Peer-reviewed article in Human Mutation reports 3-fold increase in pathogenic/likely pathogenic ENPP1 variants – - Database identified severely symptomatic patients with monoallelic heterozygous...